INTRODUCTION {#s1}
============

Percutaneous coronary intervention (PCI) is a widely used technique for treating patients with Coronary Heart Disease (CHD), including angina or an acute coronary event. In-stent restenosis (ISR) after PCI, however, remains an unsolved clinical problem \[[@R1], [@R2]\]. Compared to the bare metal stent, drug-eluting stents significantly reduced the ISR rate; however, ISR still occurs in 7% to 13% of patients receiving DES \[[@R3]\]. The mechanisms of restenosis are not fully understood yet. It is widely accepted that vascular Inflammation plays a central role in the pathogenesis of ISR, which stimulates vascular smooth muscle cells (VSMCs) proliferation and migration as well as extracellular matrix remodeling, resulting in neointema formation and eventually ISR \[[@R4]--[@R6]\].

In mammals, the Janus kinases/signal transducers and activators of transcription (JAK/STAT) pathway is the principal signaling mechanism for a wide array of inflammatory cytokines and growth factors \[[@R7], [@R8]\]. Various cytokines, growth factors, and protein tyrosine kinases communicate through the JAK/STAT pathway and regulate the transcription of numerous genes \[[@R9]--[@R11]\]. Activation of the JAK-STAT signaling pathway resulted in the production of IL-6. The JAK/STAT signaling pathways have been implicated in the pathogenesis of several diseases, including inflammatory bowel disease (IBD), especially since a JAK inhibitor recently has been shown to be effective in the treatment of ulcerative colitis \[[@R12]\]. The role of JAK/STAT pathway and their functional coupling with Ang II were examined in balloon-injured rat carotid artery. JAK and STAT proteins are both inducible in medial and neointimal VSMCs after vascular injury and were functionally coupled to AT1 \[[@R13]\]. STAT1 and STAT3 are activated during proliferation and inflammation inside atheromatous plaques and are viewed as intracellular regulators of vascular remodeling \[[@R14]\].

The suppressor of cytokine signaling-1 (SOCS1) is an inhibitor of JAK/STAT pathway activity and inhibits the biological effects of cytokines \[[@R15], [@R16]\] \[[@R17]\]. The activity of SCOS1 is regulated by its methylation status via negatively affecting its transcriptional silencing \[[@R18]--[@R20]\]. The methylation status of SOCS1 has been reported with a variety of disease, including multiple myeloma, myeloproliferative neoplasm, mantle cell lymphoma and follicular lymphoma, liver and gastric cancer, pancreatic ductal neoplasms, et al \[[@R21]--[@R26]\].

In this study, we aimed to explore the possible association between methylation status of SOCS1 and ISR in patients receiving PCI. Our purpose is to find a non-invasive biomarker to predict the ISR occurrence.

RESULTS {#s2}
=======

According to presence of ISR, all patients were divided into ISR and non-ISR groups. As shown in Table [1](#T1){ref-type="table"}, there are 47 patients in the ISR group and 415 patients in the non-ISR group. As for the demographic and clinical characteristics, patients from two groups show no significant differences in age, sex, smoking status, diabetes, body mass index (BMI), blood pressure levels, creatinine (CR), lipid profile, stent types and ejection fraction (EF) (P \> 0.05 for all, Table [1](#T1){ref-type="table"}). Similarly, the serum levels of several cytokines including IL1, IL6, and hs-CRP as well as their angiographic characteristics including vessel disease location and numbers are similar between these two groups (P \> 0.05 for all. As shown in Figure [1](#F1){ref-type="fig"}). However, the SOCS1 mRNA was significantly higher in non-ISR group compare to ISR group (P\<0.001, Figure [1](#F1){ref-type="fig"}).

###### Basic clinical characteristics of patients

                            Non-ISR(n=415)   ISR(n=47)    P value
  ------------------------- ---------------- ------------ ---------
  Age (years old)           57.1±6.6         56.3±7.9     0.324
  Sex (number)                                            
   Male                     211              27           0.241
   Female                   204              20           
  Smoker (number)                                         
    Current smoker          159              26           0.214
   Non-smoker               156              21           
  BMI (Kg/m2)               29.7±4.1         27.9±2.3     0.066
  DM                                                      
   Yes                      261              31           0.404
   No                       154              16           
  SBP (mmHg)                136.4±12.5       136.3±11.6   0.982
  DBP (mmHg)                79.8±13.6        80.7±11.4    0.18
  LDL (mmol/L)              3.7±1.2          3.9±1.1      0.485
  HDL (mmol/L)              0.95±0.4         0.89±0.3     0.141
  EF (%)                    50.8±7.1         54.8±6.9     0.231
  CR (umol/L)               76.8±9.7         77.1±10.7    0.134
  Vessel disease location                                 
   LAD                      200              22           0.974
   LCX                      100              12           
   RCA                      115              13           
  Stent type                                              
   Bare metal stent         65               10           0.213
   Drug eluting stent       350              37           
  Vessel diseased number                                  
   1                        172              21           0.894
   2                        108              11           
   3                        135              15           

DM: diabetes mellitus; SBP: systolic blood pressure, DBP: diastolic blood pressure; BMI: body mass index; CR: creatinine; EF: ejection fraction; IL-1: interleukin 1, ; IL6: interleukin 6; hs-CRP: high-sensitivity C-reactive protein levels; LAD: left anterior descending artery; Cx: left circumflex artery; RCA: right coronary artery

Categorical variables were compared by the chi-square and continuous variables were compared using Student's t-test.

![The cytokines and SOCS1 mRNA expressions between non-ISR and ISR groups](oncotarget-08-56959-g001){#F1}

There are a total of 187 patients had SOCS1 gene promoter methylation while there are 275 had no methylated SOCS1 promoter. Typical images for SOCS1 promoter methylation or unmethylation bands are shown in Figure [2](#F2){ref-type="fig"}. When all patients were stratified with SOCS1 methylation status, we found that the SOCS1 methylation status is not associated with the patients' demographic and clinical characteristics such as age, sex, diabetes, BMI, CR, lipid profile, smoking status as well as their angiographic characteristics (Table [2](#T2){ref-type="table"}). However, we found that patients with SOCS1 methylation have a higher inflammatory status, indicated by increased serum IL1, IL6 and hs-CRP levels (Figure [3](#F3){ref-type="fig"}). Of note, patients with SOCS1 methylation had a significantly lower SOCS1 mRNA levels compared to those without (Figure [3](#F3){ref-type="fig"}).

![The typical image for MSP product electrophoresis\
M, presence of SOCS1 promoter methylation band; U, presence of SOCS1 promoter unmethylation band. Patients with presence of SOCS1 promoter methylation (sample 1 and 2) were assigned into methlyation group while those with SOCS1 promoter unmethylation band were assigned into unmethylation group.](oncotarget-08-56959-g002){#F2}

###### The association between SOCS1 methylation status and characteristics of CAD patients

                            Methylation (n=187)   Unmethylation (n=275)   P value
  ------------------------- --------------------- ----------------------- ---------
  Age (years old)           56.5±8.3              56.3±7.5                0.324
  Sex (number)              0.487                                         
  Male                      90                    134                     0.241
  Female                    97                    141                     
  Smoker (number)                                                         
   Current smoker           138                   147                     0.214
  Non-smoker                49                    128                     
  DM                                                                      
   Yes                      72                    119                     0.177
   No                       115                   156                     
  BMI (Kg m-2)              28.4±2.9              27.9±2.3                0.323
  SBP (mmHg)                136.3±11.3            135.9±11.8              0.982
  DBP (mmHg)                81.4±11.7             80.8±11.5               0.18
  LDL (mmol/L)              3.8±1.1               4.0±1.1                 0.223
  HDL (mmol/L)              0.89±0.3              0.90±0.3                0.765
  EF (%)                    54.4±7.1              54.8±6.9                0.886
  CR (umol/L)               76.7±9.3              77.1±10.7               0.134
  IL1 (pg/mL)               16.5±1.9              13.6±2.1                0.023
  IL6 (pg/mL)               12.9±1.3              10.1±1.8                0.011
  Hs-CRP                    2.6±1.8               1.8±1.4                 0.017
  Vessel disease location                                                 
   LAD                      80                    142                     0.071
   LCX                      55                    57                      
   RCA                      52                    76                      
  Stent type                                                              
   Bare metal stent         35                    40                      0.252
   Drug eluting stent       200                   187                     
  Diseased vessel number                                                  
   1                        88                    105                     0.142
   2                        46                    73                      
   3                        53                    97                      

DM: diabetes mellitus; SBP: systolic blood pressure, DBP: diastolic blood pressure; BMI: body mass index; CR: creatinine; EF: ejection fraction; IL-1: interleukin 1, ; IL6: interleukin 6; hs-CRP: high-sensitivity C-reactive protein levels; LAD: left anterior descending artery; Cx: left circumflex artery; RCA: right coronary artery

Categorical variables were compared by the chi-square and continuous variables were compared using Student's t-test.
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We next analyses the correlation of SOCS1 gene promoter methylation status to the incidence of ISR in studied cohorts. For patients with SOCS1 methylation, 32 are form ISR group and 155 are from non-ISR group while for those without SOCS1 methylation, only 15 are from ISR and 260 are from non-ISR groups. Patients with ISR tend to have a significantly higher percentage of SOCS1 gene methylation (P\<0.001, Table [3](#T3){ref-type="table"}).

###### The association between SOCS1 methylation status and ISR presence of CAD patients

                        ISR   Non-ISR   P
  --------------------- ----- --------- -------
  SOCS1 methylation     32    155       0.001
  SOCS1 unmethylation   15    260       

We next conducted the Binary logistic regression analyses to determine the correlation of SOCS1 with ISR, using demographic and clinical characteristics, including diabetes, body mass index, creatinine, total cholesterol, LDL cholesterol, or smoking status as confounders. Among all the factors that we examined, our data show that SOCS1 methylation is the only factor which is closely associated with ISR incidence. Patients with SOCS1 methylation are 5.19 times more likely to develop ISR after successful PCI as opposed to those without SOCS1 methylation (P\<0.001, Table [4](#T4){ref-type="table"}).

###### Binary logistic regression analyses

  Variables in the equation                                                   
  --------------------------- ----------- ---------- ------------ ----------- -----------
  Age                         −0.007      0.027      0.066        0.798       0.993
  BMI                         −0.195      0.077      1.317        0.082       0.823
  Sex                         0.045       0.439      0.01         0.919       1.046
  SBP                         −0.019      0.019      1.029        0.31        0.981
  DBP                         −0.018      0.018      1.028        0.311       0.982
  DM                          −0.574      0.598      1.917        0.009       0.207
  LDL                         0.151       0.177      0.729        0.393       1.163
  HDL                         0.363       0.716      0.257        0.612       1.437
  CR                          −0.036      0.023      2.516        0.113       0.965
  EF                          0.081       0.03       1.079        0.208       1.084
  mRNA                        0.123       0.158      0.572        0.213       1.224
  **SOCS1 methylation**       **1.648**   **0.33**   **24.939**   **0.000**   **5.195**
  hs-CRP                      0.052       0.183      0.08         0.777       1.053
  IL6                         0.107       0.128      0.697        0.404       1.113
  IL1                         0.06        0.105      0.331        0.565       1.062
  Smoker                      0.104       0.453      0.053        0.819       1.109
  Vessel disease location     −0.205      0.243      0.715        0.398       0.814
  Diseased vessel number      −0.191      0.252      0.579        0.447       0.826
  Constant                    0.573       5.629      0.01         0.919       1.774

DISCUSSION {#s3}
==========

In this current study, we investigated the possible association between SOCS1 gene promoter methylation status from blood samples of patients with stable CAD receiving successful PCI and the incidence of ISR one year later. Our data show that SOCS1 promoter methylation is closely associated with the blood inflammatory status and more importantly, the presence of SOCS1 methylation predicts a 5.19 times higher risk to development ISR than those with SOCS1 gene unmethylation.

SOCS1 is expressed in atherosclerotic lesions and it is one of the key regulators of vascular cell responses In vivo, antisense oligodeoxynucleotides targeting SOCS3 exacerbated the atherosclerotic process in apoE−/−mice by increasing the size, leukocyte content, and chemokine expression in the lesions. Clinical significance of SOCS1 gene polymorphism in patients with coronary heart disease has been reported. There is a correlation between the SOCS1 gene polymorphism and carotid atherosclerosis. The SOCS1 gene participates in the development of coronary heart disease. SOCS1 DNA administration prevents progression to heart failure.

The proliferation and migration of VSMC play a key role in the development of ISR after coronary vessel wall injury during PCI procedure. JAK/stat activation regulates cellular behaviors including proliferation, differentiation, migration and apoptosis \[[@R27], [@R28]\]. In VSMC, STAT-3 is one of molecules involved in VSMC growth and motility \[[@R29], [@R30]\].

A number of studies indicate that SOCS1 preferentially binds to JAK kinases via its SH2 domain and inhibits signaling by shutting down JAK kinase activity via the KIR domain as well as by promoting JAK degradation via the SOCS box \[[@R31]\]. The clinical significance of SOCS1 methylation has been reported in different research filed. SOCS1 gene methylation in exon2 is frequent see in chronic myeloid leukemia patients \[[@R26]\]. Its prognostic relevance of aberrant SOCS-1 gene promoter methylation in myelodysplastic syndromes has also been reported, showing that patients with methylated SOCS-1 gene had significantly more frequent disease progression, shorter progression-free survival and median overall survival as compared to the patients with unmethylated SOCS-1 gene \[[@R32]\]. However, SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. In chronic hepatitis C patients receiving pegylated-interferon/ribavirin, SOCS-1 promoter methylation is closely associated with treatment response \[[@R33]\]. In patients with ankylosing spondylitis, methylation of SOCS-1 significantly associated with severity of patient\'s spondylopathy, sacroiliitis and acute phase reactant CRP. Patients with high serum IL-6 or TNF-α level demonstrated a significantly higher SOCS-1 methylation \[[@R34]\]. Consistent with these findings, in our study, we found the similar trend, suggesting SOCS1 methylation inhibits mRNA expression, which releases the inhibitory effect of SOCS1 on inflammatory cytokines.

SOCS-1 is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity \[[@R35]\]. Promoter methylation and expression of SOCS-1 affect clinical outcome and epithelial-mesenchymal transition in colorectal cancer. SOCS-1 hypermethylation is significantly correlated with lymph node metastasis and TNM stage. In our current study, we find SOCS1 did not associated with the severity of CAD, but closely correlated to ISR incidence. A previous study suggests that SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function, with a reduction of inflammatory cytokines produced by infiltrating immunocytes. Consistent with this finding, we observed in our study that SOCS1 methylation is correlated with increased IL1 and IL6, suggesting it is involved in the host inflammation status.

In conclusion, this is the first study reporting blood SOCS1 promoter methylation is associated with the in-stent restenosis incidence in a clinical setting. Our finding may provide a novel biomarker for ISR prediction.

Several limitations need to be addressed. Firstly, this is a single center clinical study with small sample size and only enrolled Chinese patients with stable CAD. Secondly, the molecular mechanism under which SOCS1 gene methylation affect VSMC proliferation and migration as well as inflammatory status are not included in this study.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

We enrolled 462 patients with CAD in our department from October 2010 to December 2015. CAD is defined as at least one major epicardial vessel with \>70% stenosis who planned to undergo PCI with stenting. Patients with acute myocardial infarction, chronic inflammation diseases, cancer, end-stage kidney disease, autoimmune diseases and other conditions affection host inflammation status were excluded. The clinical characteristics of patients were obtained from medical chart of each patient. Written consent was obtained from all patients, and the study protocol was approved by the Ethics Committee of our hospital.

Percutaneous coronary intervention procedure and ISR evaluation {#s4_2}
---------------------------------------------------------------

PCI was performed in the standard fashion and consisted of balloon angioplasty and stenting. In brief, patients receiving stents were treated with a combination of aspirin and clopidogrel for a week. A bolus of 10,000 U heparin was administered intravenously before the procedure. This was followed by an intravenous injection during the procedure to maintain an activated clotting time of 250 s. Balloon predilatation and stent implantation were performed according to the standard techniques. Procedural success was defined as optimal position of the stent, residual stenosis 30%, forward blood flow of thrombolysis in myocardial infarction Class 3, and no serious complications. All patients were reevaluated clinically for recurrent anginal symptoms after six to eight months. Follow-up coronary angiography was performed.12 months later. ISR was defined as stenosis greater than 50% on the follow-up angiography in the stents.

Real-time quantitative reverse transcription PCR (qRT- PCR) analysis {#s4_3}
--------------------------------------------------------------------

Venous blood samples were collected 5 min prior to stent deployment. Total RNA was extracted from mononuclear cells using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The RNA samples were treated with RNase-free recombinant DNase I (Roche, Mannheim, Germany) and subjected to reverse transcription using the Transcriptor First-Strand cDNA Synthesis kit (Roche). cDNA synthesis was achieved by incubating at 25°C for 10 min and at 42°C for 60 min, after which the reaction was inactivated by heating at 99°C for 5 min. The qRT-PCR reactions and fluorescence measurements were performed using a LightCycler 480 Real-Time PCR system (Roche). The primer/probe sequences for SOCS-1 were as follows: forward primer: 5′-TTTTCGCCCTTAGCGTGAAG-3′; reverse primer: 5′-CATCCAGGTGAAAGCGGC-3′; Quantitative amplification was performed using the following parameters: denaturation at 95°C for 10 min, followed by 50 cycles of denaturation at 95°C for 10 s, and annealing and elongation at 60°C for 30 s, with a final cooling step at 40°C for 30 s. All the sample analyses were performed in triplicate.

Methylation-specific polymerase chain reaction (MSP) {#s4_4}
----------------------------------------------------

Gnomic DNA was isolated by standard protocols from mononuclear cells. The methylation-specific polymerase chain reaction (MSP) for promoter methylation was performed as described. Briefly, treatment of DNA with bisulfite (which resulted in conversion of unmethylated cytosine to uracil, but unaffecting methylated cytosine) was performed with a commercially available kit (CpGenome DNA modification kit; Intergen, New York, NY). Primers sequence for SOCS1 promoter methylation is as follwing: Forward 5′-3′: TTG TTC GGA GGT GGA TTT (nt: 1081-1104); Reverse CGA CAC AAC TCC TAC AAC GAC CG (nt: 1218-1240). Primers sequence for SOCS1 promoter unmethylation: Forward 5′-3′: TTA TGA GTA TTT GTG TGT ATT TTT AGG TTG GTT (nt: 1072-1104); CGA CAC AAC TCC TAC AAC GAC CG (nt: 1218-1246). MSP was performed in a thermal cycler with the following cycling conditions: 95°C for 12 minutes, 35 to 45 cycles of 95°C for 45 seconds, specific annealing temperature for 30 seconds, 72°C for 30 seconds, and a final extension of 10 minutes at 72°C. The polymerase chain reaction (PCR) mixture contained 50 ng bisulfite-treated DNA, 0.2 mM deoxyribonucleoside triphosphates (dNTPs), 2 mM MgCl2, 10 pmol of each primer, 1 × PCR Buffer II, and 2.5 units of AmpliTaq Gold (PE Biosystems) in a final volume of 50 μL. Ten microliters of PCR products were loaded onto 6% nondenaturing polyacrylamide gels, electrophoresed, and visualized under ultraviolet light after staining with ethidium bromide.

Cytokines detection {#s4_5}
-------------------

Serum was obtained from blood samples (5--10 mL) from patients. Serum was quickly frozen at −70°C and stored until processed. Interleukin (IL-1) and IL6 and high-sensitivity C-reactive protein levels (hs-CRP) were measured by enzyme-linked immunosorbent assay (ELISA) technique. Laboratory determinations were performed by investigators that were blinded to clinical characteristics and patients' outcome.

Statistical analyses {#s4_6}
--------------------

Continuous variables are expressed as mean ± SD. Categorical variables are summarized as counts and percentages and were compared by the chi-square or by Fisher exact test. Continuous variables were compared using Student's t-test when normally distributed and by Mann--Whitney-U test when not normally distributed. Multivariate analysis was performed with the logistic regression model in which restenosis was used as dependent variable and potentially confounding baseline variables were used as independent variables. A value of p \< 0.05 (two-tailed) was considered statistically significant. All statistical analyses were performed with the statistical software package SPSS version 18.0 (SPSS, Inc., Chicago, Illinois).
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:   suppressor of cytokine signaling-1.

ISR

:   in-stent restenosis.

PCI

:   percutaneous coronary intervention.

MSP

:   methylation-specific polymerase chain reaction.

IL

:   interleukin.

hs-CRP

:   high-sensitivity C-reactive protein levels.
